Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.44 |
| ▸ | ESR1 | P03372 | 6/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113827 | 0.78 | ESR1 (0.52) | PTGS1ESR1PTGS2 | |
| SCHEMBL5124541 | 0.74 | ESR1 (0.54) | PTGS1ESR1ESR2KMT2APTGS2 | |
| SCHEMBL5532552 | 0.73 | CA2 (0.62) | KMT2A | |
| SCHEMBL24360466 | 0.73 | CA2 (0.62) | KMT2A | |
| SCHEMBL16926998 | 0.72 | CA1 (0.47) | PTGS1KMT2APTGS2 | |
| SCHEMBL16856551 | 0.71 | STS (0.40) | KMT2AALDH1A1 | |
| SCHEMBL28489890 | 0.70 | DRD2 (0.42) | — | |
| SCHEMBL5116884 | 0.69 | ESR1 (0.70) | PTGS1ESR1ESR2KMT2A | |
| SCHEMBL5116888 | 0.69 | ESR1 (0.70) | PTGS1ESR1ESR2KMT2A | |
| SCHEMBL24360467 | 0.69 | CA2 (0.56) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7045540-B2 | Selective estrogen receptor modulators | BRISTOL MEYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050267183-A1 | Selective estrogen receptor modulators | KALTENBACH ROBERT F | 2005-12-01 | — | — | US | disclosed |
| US-20050245602-A1 | Selective estrogen receptor modulators | KALTENBACH ROBERT F | 2005-11-03 | — | — | US | disclosed |
| US-6927224-B2 | Selective estrogen receptor modulators | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1417169-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20030105148-A1 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2003016270-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245602-A1 | Selective estrogen receptor modulators | ESR1, ESR2, GPER1 | PTGS1 150/4885ESR1 1/4885ESR2 2/4885 |
| US-20030105148-A1 | Selective estrogen receptor modulators | ESR1, GPER1, PTGIR | PTGS1 48/4885ESR1 1/4885ESR2 8/4885 |
| US-20050267183-A1 | Selective estrogen receptor modulators | ESR2, ESR1, GPER1 | PTGS1 190/4885ESR1 2/4885ESR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.